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We report a case of extraskeletal osteosarcoma (ESOS) and autopsy ﬁndings. A 35-year-old man presented with an ossiﬁed tumor
in the right thigh and lung metastasis. The lung tumors continued to develop despite multiagent chemotherapy and caused death
within8months.Autopsyrevealedmanysecondarylesionsinthelungs,especiallyintheleftlung.Histopathologically,theprimary
tumor and one of the secondary tumors showed proliferation of spindle-shaped tumor cells focally forming lace-like osteoid
material. Therefore, we made a deﬁnite diagnosis of ESOS.
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1.Introduction
Extraskeletal osteosarcoma (ESOS) is a rare malignant mes-
enchymal neoplasm in soft tissues but not directly attached
to the skeletal system. It accounts for less than 4% of all
osteosarcomas and approximately 1.2% of all soft tissue
sarcomas [1]. ESOS was ﬁrst reported by Wilson [2], and
fewer than 300 cases have been reported to date [3]. Here,
we describe a case of ESOS in the thigh and autopsy ﬁndings.
2.CaseReport
2.1. Background. A 35-year-old man presented with a
swelling in his right thigh, which he had ﬁrst noticed
one month before. His medical history was unremarkable.
On physical examination, a well-circumscribed, elastic-ﬁrm
soft tissue mass was palpated. The mass was attached
to deep fascia and was not mobile. Its maximum width
was about 16cm. The skin over the swelling was slightly
reddish and showed no signs or either ulceration or
necrosis, but was varicosed. Laboratory tests revealed slight
increase in the white blood cell count (8800) and alka-
line leukocyte phosphatase (ALP) (330), but no other
abnormalities.
2.2. Radiographic Findings. Plain radiography of the right
thigh showed a large soft tissue mass with marked calciﬁca-
tion in a radial pattern (Figure 1). Computed tomography
(CT) showed that many reﬁned calciﬁcations were scattered
inthemass,anditwasnotincontactwiththefemurorpelvis
(Figure 2). Magnetic resonance imaging (MRI) showed
that the mass was well deﬁned and located between the
sartorius muscle and tensor fasciae latae muscle. The mass
showed mixed low and iso-intensity on T1-weighted images
and mixed high and iso-intensity on T2-weighted images.
After intravenous administration of a gadolinium-based
contrast material, the tumor was well enhanced (Figure 3).
Calciﬁcations present as signal voids on all sequences. No
marked high intensity areas were observed on T2-weighted
images. There were no obvious ﬁndings of hemorrhage
or necrosis. Gallium scintigraphy showed marked hetero-
geneous accumulation especially in distal part of tumor
(Figure 4). Therefore, it was considered that diﬀerential
diagnosis contains myositis ossiﬁcans, synovial sarcoma,
extraskeletal chondrosarcoma, extraskeletal osteosarcoma,
malignant ﬁbrous histiocytoma (MFH), and liposarcoma.
Plain chest radiography revealed 8 nodular densities in
the left lung and 6 in the right, which were considered to be
metastasis (Figure 5). The largest nodule was seen at right2 Sarcoma
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Figure 1: Plain radiography at ﬁrst visit. Marked calciﬁcation was
observed in the right thigh.
Figure 2: Computed tomography of thigh. The tumor was not in
contact with the femur or its periosteum.
pulmonary hilum. The chest CT revealed multiple masses,
irregularinsize,withnopleuraleﬀusionsandnomediastinal
lymphnode hyperplasia.
Regarding the ﬁndings described above, the biopsy site
of the tumor in the right thigh was chosen to contain
calciﬁcation and well-enhanced areas with gadolinium both
of which were considered as signs of tumor aggressiveness.
Indeed,thebiopsysitechosenincludedtheantero-lateraland
distal sections of the tumor. The deep portion of the tumor
was excised along with the peripheral portion so as to obtain
both calciﬁcation and noncalciﬁcation areas.
An open biopsy specimen had malignant osteoid in lace-
like formations of long or short spindle cells with osteo-
genesis and chondrogenesis. Hypercellularity and cellular
pleomorphismwereobserved.Thenumberofmitoticﬁgures
was seen about ﬁve mitosis/10 high-power ﬁelds (HPF).
Immunohistochemically, the tumor showed reactivity with
antibodies against vimentin, desmin, and CD68. The MIB-1
labeling index was30–40%, and S-100, PAS, SMA, EMA, and
keratin showed no reactivity. Thus, the tumor was diagnosed
as ESOS.
2.3. Chemotherapy. Multiple metastases in both lungs were
considered as inoperable. Moreover, from the aspect of
pain control, there is little point in excising the primary
tumor because the patient did not feel any pain. Therefore
chemotherapy was primarily chosen as palliative treatment.
The chemotherapy regimen referred to Kanazawa University
protocol [4] was modiﬁed.
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Figure 3: Magnetic resonance imaging of the tumor. (a) T1-
weighed MRI. The mass showed mixed low and iso-intensity
signals. (b) T2-weighed MRI. The mass showed mixed high and
iso-intensity signals. (c) The tumor was enhanced remarkably by
gadolinium.
The doses of the antitumor agents were as follows: ﬁrst
and second cycles: cisplatin 460mg, doxorubicin 114mg and
caﬀeine 14.4g; third cycle: doxorubicin 106mg, ifosfamide
17.5g and mesna 10.5g. Total doses administered were
cisplatin 520mg/m2, doxorubicin 250mg/m2 and ifosfamide
16g/m2,a n dm e s n a9 . 6 g / m 2, respectively. Complications
including elevation of liver enzymes, hemorrhagic cystitis,
auditory disorder, and pancytopenia were observed. In cases
withchemotherapyinducedseverepancytopenia,the dose of
doxorubicin was reduced in the subsequent cycle.
Response to chemotherapy was evaluated after three
cycles in 2 months. According to RECIST (responseSarcoma 3
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Figure 4: Gallium scintigraphy showed increased uptake in the
primary tumor only.
evaluation criteria in solid tumors), the tumor in the thigh
was regarded as a stable disease (SD) and the pulmonary
lesion as a progressive disease (PD). There were no indi-
cations for surgery, and the patient and his family desired
more chemotherapy. Therefore, one more chemotherapy
cycle(acombination of doxorubicin, ifosfamide,and mesna)
was given, and the response was the same as the previous
cycles. Nevertheless, the pulmonary lesion maintained its
momentum conclusively occupying the left lung (Figure 6)
and causing breathing diﬃculties. After all possible palliative
care was taken, the patient died 8 months after his ﬁrst visit.
2.4. Autopsy. An autopsy was performed. The tumor was
white and about 15×10×10cm in diameter. The underlying
L
Figure 5: Plain radiography of lung. Multiple metastatic lesions in
both lungs were found at ﬁrst visit.
L
Figure 6: Plain radiography of lung at the ﬁnal follow-up.
Secondary lesion in left lung grew remarkably, and mediastinum
was pressured severely.
bone periosteum was not involved. There were numerous
pulmonarymetastaticlesions,especiallyintheleftlung.Both
lungs were almost collapsed. No other metastasis was found.
Histopathological sections of the thigh tumor and one of the
pulmonary lesions showed proliferation of spindle-shaped
tumor cells focally forming a lace-like osteoid material. The
other pulmonary metastasis sites did not have any osteoid
material (Figure 7). We made a deﬁnite diagnosis of ESOS.
3. Discussion
ESOS is a relatively rare, high-grade malignant soft tissue
neoplasm. The 5-year survival rate is as low as 25% to 37%
[5, 6]. It occurs mostly in soft tissue of the thigh (47% of
cases) [7, 8], but can occur in any part of body [9]. It occurs
predominantlyinpatientsolderthan40yearsofage,whereas
conventional osteosarcoma of bone usually occurs in the ﬁrst
or second decade of life [5–7, 10]. The patient reported here
was 35 years old, slightly younger than the usual age.
Mechanical injury has been considered as a causative
agent [11]. As with other neoplasms, the etiology is diﬃcult4 Sarcoma
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Figure 7: Histological section. (a) tumor of the thigh. Formation
of osteoid was observed (×200). (b) strong magniﬁcation of
Figure 7(a).( ×400) (c) metastatic lesion (×200).
to determine. ESOSs have been reported to have occurred in
previously irradiated areas [12]. There was no evidence of
previous trauma or irradiation in the present case.
Microscopically, unlike in myositis ossiﬁcans where the
most mature portion is located at the periphery, in ESOS,
there is often a “reverse zoning phenomenon”, that is, central
deposition of osteoid material and atypical spindle cell
proliferation at the periphery. As with this case, reverse
zoning phenomenon was observed.
ESOS is generally a high-grade sarcoma and seems to be
relatively chemoresistant, whereas osteosarcoma of bone is
generally considered to be a relatively chemosensitive form
of sarcoma [13]. Furthermore, Ahmad et al. suggested that
both cisplatin-based chemotherapy and doxorubicin-based
chemotherapy are not active against ESOS [1]. Therefore,
they asserted that ESOS should be treated as therapeu-
tically distinct from conventional osseous osteosarcoma
[1]. Goldstein-Jackson et al. reported that ESOS is better
treated with more aggressive multi-agent chemotherapy,
including doxorubicin, ifosfamide, cisplatin and possibly
methotrexate, and together with adequate surgery [14].
In the present case, however, a combination of cisplatin,
doxorubicin, ifosfamide, and caﬀeine was not eﬀective.
Autopsy revealed metastasis only in lungs, and no metas-
tasiswasfoundelsewhere.Sordilloetal.reportedthatdistant
metastasis was found in 36 of 48 patients with ESOS, and the
metastasis was to the lungs in all 36 cases [15]. Therefore,
the lung is the prime site to which ESOS metastasizes. In
the present case, though there were secondary lesions in both
lungs, osteoid material was clearly observed.
We have reported a case of extraskeletal osteosarcoma
andautopsyﬁndings.Ithadalreadymetastasizedtothelungs
at the ﬁrst visit to our hospital and did not metastasize to any
otherlocations.Thelungtumorscontinuetodevelopdespite
multi-agent chemotherapy, causing death within 8 months.
One of the secondary tumors contained osteoid material.
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